• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Jeff Patton Reflects on OCM Performance Period 4 Results, Taking on 2-Sided Risk

Video

Jeff Patton, MD, chief executive officer of Tennessee Oncology, weighs in on Oncology Care Model (OCM) performance period 4 results and taking on 2-sided risk.

Jeff Patton, MD, chief executive officer of Tennessee Oncology, weighs in on Oncology Care Model (OCM) performance period 4 results and taking on 2-sided risk.

Transcript

With OCM performance period 4 results now out, how did the results compare with the last 2 performance periods?

So, very similar. Every period we’ve generated savings against the target but every period we’ve not gotten a performance payment. The good news is as it applies to 2-sided risk, that means we would not have had any recruitment, so I think most likely we’re going to go and do 2-sided risk.

What are your thoughts on taking on 2-sided risk?

Risk is risk, so it makes everybody nervous, but with 4 consecutive performance periods where we’re in what we call the safe zone, we have a comfort level. We are investigating stop loss or reinsurance and I’ll have a lot more confidence if I have an insured downside.

Related Videos
Chesahna Kindred, MD, MBA, FAAD, board-certified dermatologist, Kindred Hair & Skin Center.
Debra Boyer, MD, MHPE, ATSF.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Plasminogen is vital in the body's coagulation process and breaking down clots | image credit: peterschreiber.media - stock.adobe.com
ISPOR 2024 Recap
Chris Pagnani, MD, PC
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.